Poorly differentiated thymic neuroendocrine carcinoma

Poorly differentiated thymic neuroendocrine carcinoma is an extremely rare and aggressive malignant tumor arising from neuroendocrine cells within the thymus gland, located in the anterior mediastinum (the area behind the breastbone and between the lungs). This tumor belongs to the broader category of thymic neuroendocrine tumors (thymic NETs) and represents the high-grade end of the spectrum, which includes small cell carcinoma and large cell neuroendocrine carcinoma of the thymus. It is classified under ICD-10 code C37 (malignant neoplasm of the thymus). The disease primarily affects the mediastinal structures and can invade surrounding tissues including the lungs, pericardium, and great vessels. It frequently metastasizes to lymph nodes, bones, liver, and lungs. Key symptoms often include chest pain, cough, shortness of breath, superior vena cava syndrome (swelling of the face and upper body due to vascular compression), and general constitutional symptoms such as weight loss and fatigue. In some cases, patients may present with paraneoplastic syndromes, including Cushing syndrome due to ectopic ACTH production, or other endocrine abnormalities. Unlike well-differentiated thymic neuroendocrine tumors, the poorly differentiated variant tends to have a more rapid clinical course and poorer prognosis. Treatment typically involves a multimodal approach. Surgical resection is attempted when feasible, often combined with platinum-based chemotherapy (such as cisplatin and etoposide regimens similar to those used for small cell lung cancer) and radiation therapy. Due to the rarity of this tumor, treatment protocols are largely extrapolated from experience with pulmonary neuroendocrine carcinomas and other thymic malignancies. Prognosis is generally poor, with high rates of recurrence and metastasis. Clinical trials and newer targeted therapies or immunotherapies are being explored, but no standardized targeted treatment has been established specifically for this entity.

Common questions about Poorly differentiated thymic neuroendocrine carcinoma